HTR

Hercules Tires Launches AG-TRAC® F-2: A Sturdy Tire Engineered for Peak Performance on Diverse Farm Terrains

Retrieved on: 
Thursday, April 4, 2024
ATD, Farmer, HTR, AG, American Tire Distributors

The AG-TRAC® F-2 is built to withstand the demands of farm work, with a durable construction that ensures long-lasting performance.

Key Points: 
  • The AG-TRAC® F-2 is built to withstand the demands of farm work, with a durable construction that ensures long-lasting performance.
  • The AG-TRAC® F-2 is the latest addition to Hercules Tires' lineup of high-quality agricultural tires, which are known for their reliability and performance.
  • For more information about the AG-TRAC® F-2 and other Hercules Tires products, visit our website at herculestirescommercial.com .
  • Join us in revolutionizing the agricultural industry with the all-new AG-TRAC® F-2 from Hercules Tire.

APPIS 2024: Healthcare Stakeholders Come Together to Prioritize Action for Better Patient Outcomes in Asia Pacific, Middle East, and Africa

Retrieved on: 
Monday, March 11, 2024
Engagement, Success, Health literacy, AME Publishing Company, Congress, Organization, Face, Health, Health equity, Real, Partnership, Novartis, Patient, Health care, Communication, Cancer, Human, HTR, Summit, GMT, Glomus tumor, Physician, Medical device

The APPIS Innovator Program and APPISx are also key components of APPIS that will bring healthcare stakeholders together throughout the year to drive positive impact for patients.

Key Points: 
  • The APPIS Innovator Program and APPISx are also key components of APPIS that will bring healthcare stakeholders together throughout the year to drive positive impact for patients.
  • The Summit aims to facilitate meaningful partnerships to address barriers to access for patients across Asia Pacific, Middle East, and Africa.
  • This year, the APPIS Summit will feature over 40 speakers, including healthcare experts, patient leaders, policymakers, and health journalists.
  • APPISx promotes country-level engagements by bringing together patient organizations and healthcare stakeholders to catalyze action-oriented solutions that address barriers to healthcare.

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Therapy, Addiction, Paroxetine, Anxiety, DMT, Mental health, SP, Imipramine, Artificial intelligence, Tri, Serotonin, BPP, Sleep, MT1, HTR, Aripiprazole, Fenfluramine, MDMA, Trazodone, Human, Mammal, Patient, Hallucination, Melatonin, DSM-IV codes, Plasma, ADHD, Literature, Research, Nefazodone, Mouse, Depression, Pharmaceutical industry

“As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.

Key Points: 
  • “As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.
  • Enveric SNDRI compounds also demonstrate distinct additional serotonin receptor binding profiles that bear similarities to those of the antidepressant Nefazodone and the anxiolytic Buspirone.
  • Enveric NSRI compounds show strong binding to SERT, as well as to the 5-HT1A receptor, known to be a therapeutically valuable target.
  • For more information about Enveric’s novel preclinical compounds spanning multiple, distinct classes of molecules, please visit: https://www.enveric.com/psybrary .

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

Retrieved on: 
Wednesday, January 3, 2024
Other Health, Research, General Health, Cannabis, Pharmaceutical, Mental Health, Natural Resources, Clinical Trials, Science, Biotechnology, Other Science, Health, IND, HTR, Depression, Mouse, Human, Addiction, Anxiety, Hallucination, Artificial intelligence, Concentration ratio, Therapy, DMT, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided an update on data underpinning the selection of EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided an update on data underpinning the selection of EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series.
  • 5-HT2A is the key receptor correlated to the neuroplastogenic activity of this emerging class of novel drugs.
  • 5-HT1A is a known important therapeutic target because other, already-approved medications for neuropsychiatric indications are known to bind this receptor.
  • HTR is a rodent behavioral model used to predict whether a molecule is likely to produce hallucinogenic effects in humans.

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Retrieved on: 
Thursday, December 28, 2023
Biotechnology, Natural Resources, Pharmaceutical, General Health, Health, Mental Health, Cannabis, Clinical Trials, Pulmonary fibrosis, IND, HTR, Depression, Half-life, Mouse, Brain, Human, Addiction, Clinical trial, Investigational New Drug, Anxiety, Hallucination, Behavior, Artificial intelligence, MB, Toxicity, Permeability, Therapy, DMT, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has named EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has named EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series.
  • Enveric plans to initiate preclinical development of EB-003 in early 2024 in preparation for an Investigational New Drug (IND) application for a first-in-human clinical trial.
  • HTR is a rodent behavioral model used to predict whether a molecule is likely to produce hallucinogenic effects in humans.
  • From the top three candidates, EB-003 was chosen as lead based on its superiority in numerous relevant measures.

Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Retrieved on: 
Tuesday, December 5, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Depression, Research, IND, Hallucination, Clinical trial, Serum, Mouse, Addiction, Artificial intelligence, Neuroplasticity, Investigational New Drug, Therapy, Anxiety, Permeability, HTR, Traffic barrier, Pharmaceutical industry

Enveric plans to select one of the compounds for preclinical development early in 2024 in anticipation of Investigational New Drug (IND) application for a first-in-human clinical trial.

Key Points: 
  • Enveric plans to select one of the compounds for preclinical development early in 2024 in anticipation of Investigational New Drug (IND) application for a first-in-human clinical trial.
  • Enveric’s research team successfully narrowed the EVM301 Series to three candidates with preclinical data indicating 5HT2A receptor binding, induction of neuroplasticity, and positive stress recovery outcomes in animal models showing no indication of hallucinations.
  • All three candidates demonstrated acceptable assessments of cellular toxicity, blood-brain barrier permeability, and differential binding to other serotonin receptors and transporters.
  • We are committed to aggressively pursuing a thorough and expedited preclinical program in 2024 in preparation for an IND application.”

Gale Debuts New Digital Archive Series on Environmental History

Retrieved on: 
Wednesday, November 1, 2023
OCR, Environmental history, Forest service, HTR, Mining, Public policy, System, United States Forest Service, History, Legislation, Conference, Organization, Biophysical environment, Bureau, Research, Grinnell, Lunch, Environment, Natural history, Report, Student, Bingham Canyon Reclamation Project, Teaching, Librarian, Record, Gale (publisher), Workflow, Free State (province), Bison, Natural Resources, Velma Bronn Johnston, Western United States, Collection, Climate change, Indigenous peoples, Government, Pamphlet, Book, Metadata, Ahmed Iqbal Ullah Race Relations Resource Centre, Charleston Conference, Agriculture, Nursing, Forestry, Video game, Hunting

FARMINGTON HILLS, Mich., Nov. 1, 2023 /PRNewswire/ -- Gale, part of Cengage Group, is introducing the first installment of its new Environmental History series of digitized primary sources. Environmental History: Conservation and Public Policy in America, 1870–1980 is the research market's first digital archive that examines the history of the environment and conservation efforts across the globe from the late 1800s onwards. The collection concentrates on the role of various government agencies, conservation organizations and individual actors who pioneered the study of the natural environment and campaigned for its protection. This new innovative series provides scholars and researchers with historical context on today's conservation movements from a variety of viewpoints, enabling new insights and connections about environmental efforts.

Key Points: 
  • Environmental History: Conservation and Public Policy in America, 1870–1980 is the research market's first digital archive that examines the history of the environment and conservation efforts across the globe from the late 1800s onwards.
  • "We created the Environmental History series in response to the interest we received from librarians and scholars on the topic," said Seth Cayley, vice president of global academic product at Gale.
  • Environmental History also includes Gale's new Related Resources feature, which links documents from the archive to relevant articles in Gale eBooks .
  • Gale will host a lunch and learn event on Environmental History during the 2023 Charleston Conference as well as showcase the new archive series at the Gale booth #71.

Ironman Introduces Mileage Coverage in Upgraded Protection Policy

Retrieved on: 
Thursday, July 6, 2023
Road, Policy, New product development, Nail, HTR, Natural rubber, Ironman, Tire manufacturing, Health insurance, Trust

HUNTERSVILLE, N.C., July 6, 2023 /PRNewswire/ -- Hercules Tire and Rubber Company (HTR) today announced a significant upgrade to its Ironman Limited Protection Policy. Effective July 1, 2023, the Ironman Tires brand, now includes mileage coverage, providing enhanced peace of mind for every tire purchased, reinforcing Ironman Tires as the "Tires to Trust." 

Key Points: 
  • HUNTERSVILLE, N.C., July 6, 2023 /PRNewswire/ -- Hercules Tire and Rubber Company (HTR) today announced a significant upgrade to its Ironman Limited Protection Policy.
  • Effective July 1, 2023, the Ironman Tires brand, now includes mileage coverage, providing enhanced peace of mind for every tire purchased, reinforcing Ironman Tires as the "Tires to Trust."
  • "The inclusion of Mileage coverage across our expanding lineup of Ironman Tires solidifies our ongoing mission to competitively position the brand as the best among tier 4 and other low-cost radials.
  • For complete details on the upgraded Ironman Limited Protection Policy, please visit www.ironmantires.com .

Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023

Retrieved on: 
Tuesday, May 30, 2023
Mental Health, Health, General Health, Research, Science, Biotechnology, Hallucination, Human, Depression, University, Therapy, University of Calgary, Anxiety, Addiction, HTR, Proxy, Pharmaceutical industry

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that research foundational to the development of the Company’s EVM201 Series and EVM301 Series is featured in a poster presentation at the 16th Annual Canadian Neuroscience Meeting (CAN 2023) being held May 28-31, 2023.

Key Points: 
  • Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that research foundational to the development of the Company’s EVM201 Series and EVM301 Series is featured in a poster presentation at the 16th Annual Canadian Neuroscience Meeting (CAN 2023) being held May 28-31, 2023.
  • The poster entitled, “Building a better psychedelic,” highlights research sponsored by Enveric and led by Professor Jaideep Bains and Dr. Sarah Cook of the Hotchkiss Brain Institute, University of Calgary.
  • The work correlates structural motifs found in certain novel tryptamine-based therapeutic drug candidates created and owned by Enveric with stress reduction and Head Twitch Response (HTR) activity in animal models.
  • For Enveric, this technology will be helpful as a screening tool in the identification of a lead candidate from our EVM301 Series.

Blue Water Partners with HTR Resorts

Retrieved on: 
Thursday, March 23, 2023
Branch, Partnership, Travel, Platte River Campground Site, Water, ME, Adirondack Mountains, Egg Harbor, CO, American Buffalo, Camping, Growth, Blue Waters Hotel, HTR, SD, Tourism, Amusement park

OCEAN CITY, Md., March 23, 2023 /PRNewswire/ -- Outdoor hospitality specialist Blue Water has recently partnered with HTR Resorts to manage operations of their properties. HTR Resort properties are best-in-class RV, camping, and glamping resorts throughout America with a focus on providing unforgettable experiences for their guests.

Key Points: 
  • OCEAN CITY, Md., March 23, 2023 /PRNewswire/ -- Outdoor hospitality specialist Blue Water has recently partnered with HTR Resorts to manage operations of their properties.
  • HTR Resort properties are best-in-class RV, camping, and glamping resorts throughout America with a focus on providing unforgettable experiences for their guests.
  • "We are excited to partner with HTR Resorts and to connect with their guests," said Todd Burbage, CEO of Blue Water.
  • "We look forward to continuing the HTR Resort expansion while ensuring the Blue Water standard of exceptional guest experiences."